Physician profile
Arej M Sawani
NPI 1407832850
$3,991.17
in general payments reported to CMS, 2019-2025
43 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2023: $601 · 2024: $1,778 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,651 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,650.77 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $426.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $406.68 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $271.28 | 2019-2025 | Tagrisso, Enhertu |
| Astellas Pharma US INC | $270.00 | 2023-2025 | Xtandi, Padcev |
| Janssen Biotech, INC. | $240.62 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Pfizer INC. | $235.87 | 2019-2025 | |
| Stemline Therapeutics INC. | $167.46 | 2023-2024 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $158.37 | 2023-2025 | Libtayo |
| Abbvie INC. | $136.20 | 2024-2025 | |
| Celgene Corporation | $130.89 | 2019-2025 | Reblozyl, Breyanzi |
| Takeda Pharmaceuticals U.S.A., INC. | $129.60 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| E.R. Squibb & Sons, L.L.C. | $117.33 | 2023-2025 | Opdualag, Opdivo |
| Glaxosmithkline, LLC. | $93.57 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $86.80 | 2024-2025 | |
| Lilly USA, LLC | $78.02 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $74.82 | 2024-2025 | Onivyde |
| Taiho Oncology, INC. | $72.73 | 2024 | |
| Array Biopharma INC | $71.77 | 2023-2025 | Braftovi, Lorbrena, Xalkori |
| Genzyme Corporation | $69.43 | 2019-2025 | |
| Puma Biotechnology, INC. | $61.84 | 2019-2025 | |
| Tempus Ai, INC | $57.20 | 2024 | |
| Daiichi Sankyo INC. | $54.50 | 2019-2025 | Enhertu |
| Eisai INC. | $48.66 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $48.51 | 2023-2025 | |
| Seagen INC. | $45.44 | 2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $43.37 | 2019-2023 | Imbruvica, Epkinly |
| Emd Serono, INC. | $34.88 | 2024 | |
| Genentech USA, INC. | $33.25 | 2019-2024 | Venclexta |
| Gilead Sciences, INC. | $30.77 | 2024-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.28 | 2025 | |
| Caris Mpi, INC. | $26.70 | 2025 | Mi Cancer Seek |
| Exelixis INC. | $24.46 | 2023 | Cabometyx |
| Progenics Pharmaceuticals, INC. | $22.96 | 2025 | |
| Pharmaessentia USA Corporation | $22.38 | 2023 | Besremi |
| Tersera Therapeutics LLC | $21.39 | 2025 | Zoladex |
| Genmab U.S., INC. | $21.24 | 2024 | Tivdak |
| Argenx US, INC. | $21.22 | 2024 | Vyvgart Hytrulo |
| Novocure INC. | $19.51 | 2023 | Optune |
| Bayer Healthcare Pharmaceuticals INC. | $19.08 | 2023 | |
| Amgen INC. | $17.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.75 | 2023 | Empaveli |
| Incyte Corporation | $17.24 | 2025 | Jakafi, Niktimvo |
| Beigene USA, INC. | $14.44 | 2024 | Brukinsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arej Sawani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.